The MANCO consortium has reached an important milestone!

The MANCO team has been searching for broadly neutralizing human monoclonal antibodies to treat COVID-19. We identified a broadly reactive SARS-CoV-2 – 87G7 – that potently neutralized Omicron and other variants of concern. Moreover we demonstrated that 87G7 can provide protection against infection with these SARS-CoV-2 variants in animal models. This is a huge step for the MANCO project!

The 87G7 antibody has been published in the journal Science Immunology.